Key facts
- This page summarizes Albert Bourla's Form 4 filing for PFIZER INC (PFE).
- 4 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 21 Dec 2021, 17:03.
Albert Bourla - 17 Dec 2021 Form 4 Insider Report for PFIZER INC (PFE)
- Reporting relationship
- Chairman & CEO, Director
- Issuer ticker
- PFE
- Reported as of
- 17 Dec 2021
- Net transaction value
- +$3,289,547
- SEC form
- 4
- Accepted by SEC
- 21 Dec 2021, 17:03:55 UTC
- Prior SEC filing
- 16 Dec 2021
- Next SEC filing
- 03 Jan 2022
- Source filing
- View source filing
- Reporting owner signature
- Susan E. Grant, by power of atty., for Albert Bourla
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Filing notes and source
Key filing fact
Albert Bourla filed Form 4 for PFIZER INC (PFE) on 21 Dec 2021.
Change
- Previous filing in this sequence was filed on 16 Dec 2021.
- Current net transaction value: +$3,289,547.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
PFE
transaction
Common Stock
Options Exercise
- Transaction value
- $2,189,387
- Shares
- +80,080
- Change %
- +65%
- Price
- $27.34
- Shares after
- 203,469
- Date
- 17 Dec 2021
- Ownership
- Direct
- Footnotes
- F1
PFE
transaction
Common Stock
Options Exercise
- Transaction value
- $1,100,160
- Shares
- +42,975
- Change %
- +21%
- Price
- $25.60
- Shares after
- 246,444
- Date
- 17 Dec 2021
- Ownership
- Direct
- Footnotes
- F2
PFE
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 3,881
- Date
- 17 Dec 2021
- Ownership
- By Rule 16b-3 Plan
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
PFE
transaction
Derivative
Stock Appreciation Rights
Options Exercise
- Transaction value
- $0
- Shares
- -153,790
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 17 Dec 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 153,790
- Exercise price
- $27.34
PFE
transaction
Derivative
Stock Appreciation Rights
Options Exercise
- Transaction value
- $0
- Shares
- -77,709
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 17 Dec 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 77,709
- Exercise price
- $25.60
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represents the number of stock units received upon the exercise and conversion of previously granted stock appreciation rights (SARs), calculated by taking the change in Pfizer common stock price (20 trading day average ending on the exercise date (Election Price of $53.791)) less the grant price of the SAR plus accumulated dividends from the grant date, times the number of SARs exercised. This value is divided by the Election Price to determine the number of stock units. The stock units and accumulated dividend units will be settled in Pfizer common stock on the SAR original settlement date, the fifth anniversary of grant.
Footnote F2
Represents the number of stock units received upon the exercise and conversion of previously granted stock appreciation rights (SARs), calculated by taking the change in Pfizer common stock price (20 trading day average ending on the exercise date (Election Price of $53.791)) less the grant price of the SAR plus accumulated dividends from the grant date, times the number of SARs exercised. This value is divided by the Election Price to determine the number of stock units. The stock units and accumulated dividend units will be settled in Pfizer common stock on the SAR original settlement date, the seventh anniversary of grant.